Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
Cellectis S.A., a French biopharmaceutical company, filed this Form 6-K on October 16, 2025, to report on an Investors R&D Day and the release of clinical data for its lead asset, lasme-cel (UCART22). The filing focuses on the BALLI-01 Phase 1 study evaluating lasme-cel for transplant-ineligible patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in the third line of therapy or beyond.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding clinical trial progress rather than a periodic financial statement.
Material Changes and Clinical Highlights
The primary material update is the release of Phase 1 data for lasme-cel, demonstrating significant efficacy and safety in heavily pretreated patients:
- Efficacy: Overall Response Rate (ORR) reached 68% with Cellectis-manufactured product (Process 2), rising to 100% in the target Phase 2 population (n=9). Complete Remission (CR/CRi) rates were 56% in this target subset.
- MRD-Negativity: Approximately 80% of responders in the target Phase 2 population achieved Minimal Residual Disease (MRD)-negative status.
- Transplant Eligibility: 100% of patients in the target Phase 2 population became eligible for hematopoietic stem cell transplantation (HSCT), with 78% proceeding to transplant.
- Heavily Pretreated Cohort: Among 11 patients previously treated with all three targeted therapies (inotuzumab, blinatumomab, and CD19 CAR-T), 8 responded and 7 achieved MRD-negative status.
- Safety: The therapy was generally well-tolerated. Cytokine Release Syndrome (CRS) occurred in 2.5% of patients and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in 5%. Only one dose-limiting toxicity was reported.
- Durability: Median Overall Survival (OS) was 14.8 months for patients achieving MRD-negative CR/CRi.
Guidance, Outlook, and Management Commentary
Following successful End-of-Phase 1 meetings with the FDA and EMA, Cellectis has established a registration path for lasme-cel as a bridge to transplant. Management provided the following timeline:
- Phase 2 Initiation: The first patient in the pivotal Phase 2 study is expected to be enrolled in Q4 2025.
- Regulatory Submission: The Company anticipates submitting a Biologics License Application (BLA) in 2028.
The filing notes that survival curves suggest a clear benefit for patients who proceed to HSCT following lasme-cel therapy compared to those who do not.
Investor Verification Checklist
- Verify the enrollment timeline for the pivotal Phase 2 study in Q4 2025.
- Confirm the manufacturing consistency of Process 2 (Cellectis-manufactured) versus Process 1 (CDMO) as efficacy differed significantly.
- Monitor the long-term durability data for the 14.8-month median OS figure as the study matures.
- Review the specific criteria for the "target Phase 2 population" (age ≤ 50, Process 2, Dose Level 3) to understand the generalizability of the 100% ORR.
- Track the company's cash burn rate and funding status, as no financial data was included in this specific filing.